BioXcel Therapeutics (BTAI) Long-Term Debt Repayments (2026)
BioXcel Therapeutics (BTAI) recorded quarterly Long-Term Debt Repayments of $2.5 million in Q1 2026.
BioXcel Therapeutics (BTAI) Long-Term Debt Repayments (2026) Analysis & Trends
BioXcel Therapeutics' Long-Term Debt Repayments history runs 1 years deep, the most recent figure standing at $2.5 million for Q1 2026.
- In Q1 2026, Long-Term Debt Repayments changed N/A year-over-year to $2.5 million; the TTM figure through Mar 2026 stood at $2.5 million (changed N/A YoY), while the FY2024 annual figure was $2.5 million, changed N/A from the prior year.
- Long-Term Debt Repayments was $2.5 million for Q1 2026 at BioXcel Therapeutics.
- In the past five years, Long-Term Debt Repayments ranged from a high of $2.5 million in Q1 2026 to a low of $2.5 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 23.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | - |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | - |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | - |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 216,000.00 |
| 10 | BioXcel Therapeutics | 25.46 Mn | 25.46 Mn | -77,000.00 | 2.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.50 Mn |
| Mar 31, 2026 | 2.50 Mn |